<?xml version="1.0" encoding="UTF-8"?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns"
         xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns
         http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
<!-- Created by igraph -->
  <key id="v_name" for="node" attr.name="name" attr.type="double"/>
  <key id="v_type" for="node" attr.name="type" attr.type="string"/>
  <key id="v_identifier" for="node" attr.name="identifier" attr.type="string"/>
  <key id="v_source" for="node" attr.name="source" attr.type="string"/>
  <key id="v_label" for="node" attr.name="label" attr.type="string"/>
  <key id="v_indication" for="node" attr.name="indication" attr.type="string"/>
  <key id="v_pharmacodynamics" for="node" attr.name="pharmacodynamics" attr.type="string"/>
  <key id="v_mechanism_of_action" for="node" attr.name="mechanism_of_action" attr.type="string"/>
  <key id="v_group" for="node" attr.name="group" attr.type="string"/>
  <key id="v_category" for="node" attr.name="category" attr.type="string"/>
  <key id="v_description" for="node" attr.name="description" attr.type="string"/>
  <key id="v_state" for="node" attr.name="state" attr.type="string"/>
  <key id="v_protein_binding" for="node" attr.name="protein_binding" attr.type="string"/>
  <key id="v_half_life" for="node" attr.name="half_life" attr.type="string"/>
  <key id="v_atc_3" for="node" attr.name="atc_3" attr.type="string"/>
  <key id="v_atc_1" for="node" attr.name="atc_1" attr.type="string"/>
  <key id="v_molecular_weight" for="node" attr.name="molecular_weight" attr.type="string"/>
  <key id="v_atc_2" for="node" attr.name="atc_2" attr.type="string"/>
  <key id="v_tpsa" for="node" attr.name="tpsa" attr.type="string"/>
  <key id="v_atc_4" for="node" attr.name="atc_4" attr.type="string"/>
  <key id="v_clogp" for="node" attr.name="clogp" attr.type="string"/>
  <key id="v_pathway" for="node" attr.name="pathway" attr.type="string"/>
  <key id="v_mondo_name" for="node" attr.name="mondo_name" attr.type="string"/>
  <key id="v_umls_description" for="node" attr.name="umls_description" attr.type="boolean"/>
  <key id="v_group_name_bert" for="node" attr.name="group_name_bert" attr.type="string"/>
  <key id="v_mondo_definition" for="node" attr.name="mondo_definition" attr.type="string"/>
  <key id="v_orphanet_epidemiology" for="node" attr.name="orphanet_epidemiology" attr.type="string"/>
  <key id="v_orphanet_definition" for="node" attr.name="orphanet_definition" attr.type="string"/>
  <key id="v_orphanet_prevalence" for="node" attr.name="orphanet_prevalence" attr.type="string"/>
  <key id="v_group_id_bert" for="node" attr.name="group_id_bert" attr.type="string"/>
  <key id="v_orphanet_management_and_treatment" for="node" attr.name="orphanet_management_and_treatment" attr.type="string"/>
  <key id="v_mondo_id" for="node" attr.name="mondo_id" attr.type="double"/>
  <key id="v_orphanet_clinical_description" for="node" attr.name="orphanet_clinical_description" attr.type="string"/>
  <key id="v_mayo_risk_factors" for="node" attr.name="mayo_risk_factors" attr.type="string"/>
  <key id="v_mayo_causes" for="node" attr.name="mayo_causes" attr.type="string"/>
  <key id="v_mayo_symptoms" for="node" attr.name="mayo_symptoms" attr.type="string"/>
  <key id="v_mayo_see_doc" for="node" attr.name="mayo_see_doc" attr.type="string"/>
  <key id="v_mayo_prevention" for="node" attr.name="mayo_prevention" attr.type="boolean"/>
  <key id="v_mayo_complications" for="node" attr.name="mayo_complications" attr.type="boolean"/>
  <key id="e_type" for="edge" attr.name="type" attr.type="string"/>
  <key id="e_display_relation" for="edge" attr.name="display_relation" attr.type="string"/>
  <graph id="G" edgedefault="directed">
    <node id="n0">
      <data key="v_name">197</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">1432</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">MAPK14</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n1">
      <data key="v_name">601</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">25</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">ABL1</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n2">
      <data key="v_name">1050</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">3309</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">HSPA5</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n3">
      <data key="v_name">1497</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">2950</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">GSTP1</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n4">
      <data key="v_name">1530</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">613</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">BCR</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n5">
      <data key="v_name">1618</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">3717</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">JAK2</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n6">
      <data key="v_name">1980</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">673</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">BRAF</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n7">
      <data key="v_name">2003</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">1408</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">CRY2</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n8">
      <data key="v_name">2533</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">1407</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">CRY1</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n9">
      <data key="v_name">3130</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">51428</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">DDX41</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n10">
      <data key="v_name">3438</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">861</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">RUNX1</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n11">
      <data key="v_name">3624</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">5187</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">PER1</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n12">
      <data key="v_name">3631</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">240</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">ALOX5</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n13">
      <data key="v_name">3914</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">23532</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">PRAME</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n14">
      <data key="v_name">4084</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">332</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">BIRC5</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n15">
      <data key="v_name">4344</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">7490</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">WT1</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n16">
      <data key="v_name">4444</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">768</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">CA9</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n17">
      <data key="v_name">4883</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">406</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">ARNTL</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n18">
      <data key="v_name">4943</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">3161</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">HMMR</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n19">
      <data key="v_name">5100</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">8864</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">PER2</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n20">
      <data key="v_name">5129</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">7015</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">TERT</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n21">
      <data key="v_name">5151</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">26040</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">SETBP1</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n22">
      <data key="v_name">5307</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">4893</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">NRAS</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n23">
      <data key="v_name">6424</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">8863</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">PER3</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n24">
      <data key="v_name">6671</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">1441</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">CSF3R</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n25">
      <data key="v_name">6926</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">3440</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">IFNA2</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n26">
      <data key="v_name">9024</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">171023</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">ASXL1</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n27">
      <data key="v_name">9540</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">55500</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">ETNK1</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n28">
      <data key="v_name">11148</data>
      <data key="v_type">gene/protein</data>
      <data key="v_identifier">5657</data>
      <data key="v_source">NCBI</data>
      <data key="v_label">PRTN3</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n29">
      <data key="v_name">14207</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB00619</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Imatinib</data>
      <data key="v_indication">For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).</data>
      <data key="v_pharmacodynamics">Imatinib is an antineoplastic agent and a 2-phenylaminopyrimidine derivative that is used to treat chronic myelogenous leukemia. It works as a specific inhibitor of a number of tyrosine kinase enzymes. Chronic myelogenous leukemia is associated with the Philadelphia chromosome promoting the generation of BCR-ABL mutation, which results from the combination of two genes, known as BCR and ABL. BCR-ABL generates a fusion protein that acts as a constitutively active tyrosine kinase and imatinib works to inhibit this constitutive enzymatic activity. </data>
      <data key="v_mechanism_of_action">Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML). It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib also inhibits the receptor tyrosine kinases for platelet derived growth factor (PDGF) and stem cell factor (SCF) - called c-kit. Imatinib was identified in the late 1990s by Dr Brian J. Druker. Its development is an excellent example of rational drug design. Soon after identification of the bcr-abl target, the search for an inhibitor began. Chemists used a high-throughput screen of chemical libraries to identify the molecule 2-phenylaminopyrimidine. This lead compound was then tested and modified by the introduction of methyl and benzamide groups to give it enhanced binding properties, resulting in imatinib.</data>
      <data key="v_group">Imatinib is approved.</data>
      <data key="v_category">Imatinib is part of Acids, Carbocyclic ; Amides ; Antineoplastic Agents ; Antineoplastic and Immunomodulating Agents ; BCRP/ABCG2 Inhibitors ; BCRP/ABCG2 Substrates ; Benzamides and benzamide derivatives ; Benzene Derivatives ; Benzoates ; BSEP/ABCB11 Substrates ; Cardiotoxic antineoplastic agents ; Cytochrome P-450 CYP1A2 Substrates ; Cytochrome P-450 CYP2C19 Substrates ; Cytochrome P-450 CYP2C8 Substrates ; Cytochrome P-450 CYP2C9 Inhibitors ; Cytochrome P-450 CYP2C9 Inhibitors (moderate) ; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ; Cytochrome P-450 CYP2C9 Substrates ; Cytochrome P-450 CYP2D6 Inhibitors ; Cytochrome P-450 CYP2D6 Inhibitors (weak) ; Cytochrome P-450 CYP2D6 Substrates ; Cytochrome P-450 CYP3A Inhibitors ; Cytochrome P-450 CYP3A Substrates ; Cytochrome P-450 CYP3A4 Inhibitors ; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) ; Cytochrome P-450 CYP3A4 Substrates ; Cytochrome P-450 CYP3A5 Inhibitors ; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) ; Cytochrome P-450 CYP3A5 Substrates ; Cytochrome P-450 CYP3A7 Inhibitors ; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) ; Cytochrome P-450 CYP3A7 Substrates ; Cytochrome P-450 Enzyme Inhibitors ; Cytochrome P-450 Substrates ; Drugs causing inadvertant photosensitivity ; Enzyme Inhibitors ; Highest Risk QTc-Prolonging Agents ; Immunosuppressive Agents ; Kinase Inhibitor ; Myelosuppressive Agents ; OCT1 substrates ; OCT2 Inhibitors ; P-glycoprotein inhibitors ; P-glycoprotein substrates ; Photosensitizing Agents ; Piperazines ; Protein Kinase Inhibitors ; Pyrimidines ; QTc Prolonging Agents ; Tyrosine Kinase Inhibitors.</data>
      <data key="v_description">Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.</data>
      <data key="v_state">Imatinib is a solid.</data>
      <data key="v_protein_binding">95% protein bound, mostly to albumin and alpha-1-acid glycoprotein. </data>
      <data key="v_half_life">Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively. </data>
      <data key="v_atc_3">Imatinib is pharmacologically related to other antineoplastic agents.</data>
      <data key="v_atc_1">Imatinib is anatomically related to antineoplastic and immunomodulating agents.</data>
      <data key="v_molecular_weight">The molecular weight is 493.62.</data>
      <data key="v_atc_2">Imatinib is in the therapeutic group of antineoplastic agents.</data>
      <data key="v_tpsa">Imatinib has a topological polar surface area of 86.28.</data>
      <data key="v_atc_4">The chemical and functional group of  is protein kinase inhibitors.</data>
      <data key="v_clogp">The log p value of  is 4.38.</data>
      <data key="v_pathway">Imatinib uses Imatinib Inhibition of BCR-ABL.</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n30">
      <data key="v_name">14780</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB00987</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Cytarabine</data>
      <data key="v_indication">For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.</data>
      <data key="v_pharmacodynamics">Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the \S\&quot; phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.&quot;</data>
      <data key="v_mechanism_of_action">Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported.</data>
      <data key="v_group">Cytarabine is approved and investigational.</data>
      <data key="v_category">Cytarabine is part of Agents Causing Muscle Toxicity ; Anti-Infective Agents ; Antimetabolites ; Antineoplastic Agents ; Antineoplastic and Immunomodulating Agents ; Arabinonucleosides ; Carbohydrates ; Cardiotoxic antineoplastic agents ; Cytidine Deaminase Substrates ; Cytochrome P-450 CYP3A Substrates ; Cytochrome P-450 CYP3A4 Substrates ; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ; Cytochrome P-450 Substrates ; Glycosides ; Immunologic Factors ; Immunosuppressive Agents ; Myelosuppressive Agents ; Narrow Therapeutic Index Drugs ; Noxae ; Nucleic Acid Synthesis Inhibitors ; Nucleic Acids, Nucleotides, and Nucleosides ; Nucleoside Metabolic Inhibitor ; Nucleosides ; OCT1 substrates ; Pyrimidine Analogues ; Pyrimidine Nucleosides ; Pyrimidines ; Ribonucleosides ; Toxic Actions.</data>
      <data key="v_description">A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)</data>
      <data key="v_state">Cytarabine is a solid.</data>
      <data key="v_protein_binding">13%</data>
      <data key="v_half_life">The half-life is 10 minutes</data>
      <data key="v_atc_3">Cytarabine is pharmacologically related to antimetabolites and other antineoplastic agents.</data>
      <data key="v_atc_1">Cytarabine is anatomically related to antineoplastic and immunomodulating agents and antineoplastic and immunomodulating agents.</data>
      <data key="v_molecular_weight">The molecular weight is 243.22.</data>
      <data key="v_atc_2">Cytarabine is in the therapeutic group of antineoplastic agents and antineoplastic agents.</data>
      <data key="v_tpsa">Cytarabine has a topological polar surface area of 128.61.</data>
      <data key="v_atc_4">The chemical and functional group of  is pyrimidine analogues and combinations of antineoplastic agents.</data>
      <data key="v_clogp">The log p value of  is -2.2.</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n31">
      <data key="v_name">14794</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB01254</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Dasatinib</data>
      <data key="v_indication">For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.</data>
      <data key="v_pharmacodynamics">Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor</data>
      <data key="v_mechanism_of_action">Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR&amp;beta;. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression. </data>
      <data key="v_group">Dasatinib is approved and investigational.</data>
      <data key="v_category">Dasatinib is part of Antineoplastic Agents ; Antineoplastic and Immunomodulating Agents ; BCRP/ABCG2 Inhibitors ; BCRP/ABCG2 Substrates ; Cytochrome P-450 CYP1A2 Substrates ; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ; Cytochrome P-450 CYP3A Inhibitors ; Cytochrome P-450 CYP3A Substrates ; Cytochrome P-450 CYP3A4 Inhibitors ; Cytochrome P-450 CYP3A4 Inhibitors (weak) ; Cytochrome P-450 CYP3A4 Substrates ; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ; Cytochrome P-450 CYP3A5 Substrates ; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index ; Cytochrome P-450 Enzyme Inhibitors ; Cytochrome P-450 Substrates ; Drugs causing inadvertant photosensitivity ; Enzyme Inhibitors ; Immunosuppressive Agents ; Kinase Inhibitor ; Myelosuppressive Agents ; Narrow Therapeutic Index Drugs ; P-glycoprotein inhibitors ; P-glycoprotein substrates ; P-glycoprotein substrates with a Narrow Therapeutic Index ; Photosensitizing Agents ; Potential QTc-Prolonging Agents ; Protein Kinase Inhibitors ; Pyrimidines ; QTc Prolonging Agents ; Sulfur Compounds ; Thiazoles ; Tyrosine Kinase Inhibitors.</data>
      <data key="v_description">Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.</data>
      <data key="v_state">Dasatinib is a solid.</data>
      <data key="v_protein_binding">96%</data>
      <data key="v_half_life">The overall mean terminal half-life of dasatinib is 3-5 hours.</data>
      <data key="v_atc_3">Dasatinib is pharmacologically related to other antineoplastic agents.</data>
      <data key="v_atc_1">Dasatinib is anatomically related to antineoplastic and immunomodulating agents.</data>
      <data key="v_molecular_weight">The molecular weight is 488.01.</data>
      <data key="v_atc_2">Dasatinib is in the therapeutic group of antineoplastic agents.</data>
      <data key="v_tpsa">Dasatinib has a topological polar surface area of 106.51.</data>
      <data key="v_atc_4">The chemical and functional group of  is protein kinase inhibitors.</data>
      <data key="v_clogp">The log p value of  is 2.38.</data>
      <data key="v_pathway">Dasatinib uses Dasatinib Inhibition of BCR-ABL.</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n32">
      <data key="v_name">14849</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB00888</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Mechlorethamine</data>
      <data key="v_indication">For the palliative treatment of Hodgkin&apos;s disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.</data>
      <data key="v_pharmacodynamics">Mechlorethamine also known as mustine, nitrogen mustard, and HN2, is the prototype anticancer chemotherapeutic drug. Successful clinical use of mechlorethamine gave birth to the field of anticancer chemotherapy. The drug is an analogue of mustard gas and was derived from toxic gas warfare research. Mechlorethamine is a nitrogen mustard alkylating agent. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.</data>
      <data key="v_mechanism_of_action">Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. Mechlorethamine is cell cycle phase-nonspecific.</data>
      <data key="v_group">Mechlorethamine is approved and investigational.</data>
      <data key="v_category">Mechlorethamine is part of Alkylating Activity ; Alkylating Drugs ; Antineoplastic Agents ; Antineoplastic Agents, Alkylating ; Antineoplastic and Immunomodulating Agents ; Cardiotoxic antineoplastic agents ; Cholinesterase Inhibitors ; Compounds used in a research, industrial, or household setting ; Hydrocarbons, Halogenated ; Immunosuppressive Agents ; Irritants ; Mustard Compounds ; Myelosuppressive Agents ; Narrow Therapeutic Index Drugs ; Nitrogen Mustard Analogues ; Nitrogen Mustard Compounds ; Noxae ; Poisons ; Toxic Actions.</data>
      <data key="v_description">A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin&apos;s disease and lymphomas. It causes severe gastrointestinal and bone marrow damage.</data>
      <data key="v_state">Mechlorethamine is a solid.</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">The half-life is 15 minutes</data>
      <data key="v_atc_3">Mechlorethamine is pharmacologically related to alkylating agents.</data>
      <data key="v_atc_1">Mechlorethamine is anatomically related to antineoplastic and immunomodulating agents.</data>
      <data key="v_molecular_weight">The molecular weight is 156.05.</data>
      <data key="v_atc_2">Mechlorethamine is in the therapeutic group of antineoplastic agents.</data>
      <data key="v_tpsa">Mechlorethamine has a topological polar surface area of 3.24.</data>
      <data key="v_atc_4">The chemical and functional group of  is nitrogen mustard analogues.</data>
      <data key="v_clogp">The log p value of  is 1.2.</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n33">
      <data key="v_name">15030</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB08901</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Ponatinib</data>
      <data key="v_indication">Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">Ponatinib is a multi-target kinase inhibitor. Its primary cellular target is the Bcr-Abl tyrosine kinase protein which is constitutively active and promotes the progression of CML. This protein arises from the fused Bcr and Abl gene- what is commonly known as the Philadelphia chromosome. Ponatinib is unique in that it is especially useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of Abl and T315I mutant kinases. The T315I mutation confers resistance in cells as it prevents other Bcr-Abl inhibitors from binding to the Abl kinase. Other targets that ponatinib inhibits are members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. A decrease in tumour size expressing native or T315I mutant BCR-ABL have been observed in rats. </data>
      <data key="v_group">Ponatinib is approved and investigational.</data>
      <data key="v_category">Ponatinib is part of Antineoplastic Agents ; Antineoplastic and Immunomodulating Agents ; BCRP/ABCG2 Inhibitors ; BCRP/ABCG2 Substrates ; Cytochrome P-450 CYP2C8 Inhibitors ; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) ; Cytochrome P-450 CYP2C8 Substrates ; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ; Cytochrome P-450 CYP2D6 Substrates ; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ; Cytochrome P-450 CYP3A Substrates ; Cytochrome P-450 CYP3A4 Substrates ; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ; Cytochrome P-450 CYP3A5 Substrates ; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index ; Cytochrome P-450 Enzyme Inhibitors ; Cytochrome P-450 Substrates ; Enzyme Inhibitors ; Hepatotoxic Agents ; Immunosuppressive Agents ; Kinase Inhibitor ; Myelosuppressive Agents ; Narrow Therapeutic Index Drugs ; P-glycoprotein inhibitors ; P-glycoprotein substrates ; P-glycoprotein substrates with a Narrow Therapeutic Index ; Protein Kinase Inhibitors ; Tyrosine Kinase Inhibitors.</data>
      <data key="v_description">Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.</data>
      <data key="v_state">Ponatinib is a solid.</data>
      <data key="v_protein_binding">&gt; 99% bound to plasma proteins. </data>
      <data key="v_half_life">After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours). </data>
      <data key="v_atc_3">Ponatinib is pharmacologically related to other antineoplastic agents.</data>
      <data key="v_atc_1">Ponatinib is anatomically related to antineoplastic and immunomodulating agents.</data>
      <data key="v_molecular_weight">The molecular weight is 532.57.</data>
      <data key="v_atc_2">Ponatinib is in the therapeutic group of antineoplastic agents.</data>
      <data key="v_tpsa">Ponatinib has a topological polar surface area of 65.77.</data>
      <data key="v_atc_4">The chemical and functional group of  is protein kinase inhibitors.</data>
      <data key="v_clogp">The log p value of  is 5.77.</data>
      <data key="v_pathway">Ponatinib uses Ponatinib Inhibition of BCR-ABL.</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n34">
      <data key="v_name">15134</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB01005</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Hydroxyurea</data>
      <data key="v_indication">For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.</data>
      <data key="v_pharmacodynamics">Hydroxyurea has dose-dependent synergistic activity with cisplatin &lt;i&gt;in vitro&lt;/i&gt;. &lt;i&gt;In vivo&lt;/i&gt; Hydroxyurea showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Hydroxyurea was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to Hydroxyurea 4 hours before cisplatin produced the greatest interaction.</data>
      <data key="v_mechanism_of_action">Hydroxyurea is converted to a free radical nitroxide (NO) in vivo, and transported by diffusion into cells where it quenches the tyrosyl free radical at the active site of the M2 protein subunit of ribonucleotide reductase, inactivating the enzyme. The entire replicase complex, including ribonucleotide reductase, is inactivated and DNA synthesis is selectively inhibited, producing cell death in S phase and synchronization of the fraction of cells that survive. Repair of DNA damaged by chemicals or irradiation is also inhibited by hydroxyurea, offering potential synergy between hydroxyurea and radiation or alkylating agents. Hydroxyurea also increases the level of fetal hemoglobin, leading to a reduction in the incidence of vasoocclusive crises in sickle cell anemia. Levels of fetal hemoglobin increase in response to activation of soluble guanylyl cyclase (sGC) by hydroxyurea-derived NO.</data>
      <data key="v_group">Hydroxyurea is approved.</data>
      <data key="v_category">Hydroxyurea is part of Antineoplastic Agents ; Antineoplastic and Immunomodulating Agents ; Antisickling Agents ; Cytochrome P-450 CYP2D6 Inhibitors ; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ; Cytochrome P-450 Enzyme Inhibitors ; Enzyme Inhibitors ; Hematologic Agents ; Immunosuppressive Agents ; Myelosuppressive Agents ; Narrow Therapeutic Index Drugs ; Nucleic Acid Synthesis Inhibitors.</data>
      <data key="v_description">An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.</data>
      <data key="v_state">Hydroxyurea is a solid.</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">The half-life is 3-4 hours</data>
      <data key="v_atc_3">Hydroxyurea is pharmacologically related to other antineoplastic agents.</data>
      <data key="v_atc_1">Hydroxyurea is anatomically related to antineoplastic and immunomodulating agents.</data>
      <data key="v_molecular_weight">The molecular weight is 76.06.</data>
      <data key="v_atc_2">Hydroxyurea is in the therapeutic group of antineoplastic agents.</data>
      <data key="v_tpsa">Hydroxyurea has a topological polar surface area of 75.35.</data>
      <data key="v_atc_4">The chemical and functional group of  is other antineoplastic agents.</data>
      <data key="v_clogp">The log p value of  is -1.8.</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n35">
      <data key="v_name">15187</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB04868</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Nilotinib</data>
      <data key="v_indication">For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).</data>
      <data key="v_pharmacodynamics">Nilotinib is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML).</data>
      <data key="v_mechanism_of_action">Chronic myelogenous leukaemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein. Nilotinib fits into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib, over-riding resistance caused by mutations. The ability of AMN107 to inhibit TEL-platelet-derived growth factor receptor-beta (TEL-PDGFRbeta), which causes chronic myelomonocytic leukaemia, and FIP1-like-1-PDGFRalpha, which causes hypereosinophilic syndrome, suggests potential use of AMN107 for myeloproliferative diseases characterised by these kinase fusions (Stover et al, 2005; Weisberg et al, 2005). AMN107 also inhibits the c-Kit receptor kinase, including the D816V-mutated variant of KIT, at pharmacologically achievable concentrations, supporting potential utility in the treatment of mastocytosis, and gastrointestinal stromal tumours (Weisberg et al, 2005; von Bubnoff et al, 2005; Gleixner et al, 2006).</data>
      <data key="v_group">Nilotinib is approved and investigational.</data>
      <data key="v_category">Nilotinib is part of Antineoplastic Agents ; Antineoplastic and Immunomodulating Agents ; BCRP/ABCG2 Inhibitors ; BCRP/ABCG2 Substrates ; Cytochrome P-450 CYP2B6 Inducers ; Cytochrome P-450 CYP2B6 Inducers (strength unknown) ; Cytochrome P-450 CYP2C8 Inducers ; Cytochrome P-450 CYP2C8 Inducers (strength unknown) ; Cytochrome P-450 CYP2C8 Inhibitors ; Cytochrome P-450 CYP2C8 Inhibitors (moderate) ; Cytochrome P-450 CYP2C9 Inhibitors ; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ; Cytochrome P-450 CYP2D6 Inhibitors ; Cytochrome P-450 CYP2D6 Inhibitors (moderate) ; Cytochrome P-450 CYP3A Inhibitors ; Cytochrome P-450 CYP3A Substrates ; Cytochrome P-450 CYP3A4 Inhibitors ; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) ; Cytochrome P-450 CYP3A4 Inhibitors (strong) ; Cytochrome P-450 CYP3A4 Substrates ; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ; Cytochrome P-450 Enzyme Inducers ; Cytochrome P-450 Enzyme Inhibitors ; Cytochrome P-450 Substrates ; Drugs causing inadvertant photosensitivity ; Highest Risk QTc-Prolonging Agents ; Hyperglycemia-Associated Agents ; Immunosuppressive Agents ; Kinase Inhibitor ; Myelosuppressive Agents ; Narrow Therapeutic Index Drugs ; OATP1B1/SLCO1B1 Inhibitors ; P-glycoprotein inhibitors ; P-glycoprotein substrates ; P-glycoprotein substrates with a Narrow Therapeutic Index ; Photosensitizing Agents ; Protein Kinase Inhibitors ; QTc Prolonging Agents ; Tyrosine Kinase Inhibitors ; UGT1A1 Inhibitors.</data>
      <data key="v_description">Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.</data>
      <data key="v_state">Nilotinib is a solid.</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">The half-life is 15 hours</data>
      <data key="v_atc_3">Nilotinib is pharmacologically related to other antineoplastic agents.</data>
      <data key="v_atc_1">Nilotinib is anatomically related to antineoplastic and immunomodulating agents.</data>
      <data key="v_molecular_weight">The molecular weight is 529.53.</data>
      <data key="v_atc_2">Nilotinib is in the therapeutic group of antineoplastic agents.</data>
      <data key="v_tpsa">Nilotinib has a topological polar surface area of 97.62.</data>
      <data key="v_atc_4">The chemical and functional group of  is protein kinase inhibitors.</data>
      <data key="v_clogp">The log p value of  is 5.69.</data>
      <data key="v_pathway">Nilotinib uses Nilotinib Inhibition of BCR-ABL.</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n36">
      <data key="v_name">15429</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB00309</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Vindesine</data>
      <data key="v_indication">For the treatment of acute leukaemia, malignant lymphoma, Hodgkin&apos;s disease, acute erythraemia and acute panmyelosis</data>
      <data key="v_pharmacodynamics">Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer. Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in &lt;i&gt;in vitro&lt;/i&gt; studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Vindesine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Vindesine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine.</data>
      <data key="v_mechanism_of_action">Vindesine acts by causing the arrest of cells in metaphase mitosis through its inhibition tubulin mitotic funcitoning. The drug is cell-cycle specific for the S phase.</data>
      <data key="v_group">Vindesine is approved and investigational.</data>
      <data key="v_category">Vindesine is part of Alkaloids ; Antimitotic Agents ; Antineoplastic Agents ; Antineoplastic Agents, Phytogenic ; Antineoplastic and Immunomodulating Agents ; Cardiotoxic antineoplastic agents ; Cytochrome P-450 CYP3A Substrates ; Cytochrome P-450 CYP3A4 Substrates ; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ; Cytochrome P-450 Substrates ; Heterocyclic Compounds, Fused-Ring ; Immunosuppressive Agents ; Indole Alkaloids ; Indoles ; Mitosis Modulators ; Myelosuppressive Agents ; Narrow Therapeutic Index Drugs ; Secologanin Tryptamine Alkaloids ; Tubulin Modulators ; Vinca Alkaloids.</data>
      <data key="v_description">Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).</data>
      <data key="v_state">Vindesine is a solid.</data>
      <data key="v_protein_binding">65-75%</data>
      <data key="v_half_life">The half-life is 24 hours.</data>
      <data key="v_atc_3">Vindesine is pharmacologically related to plant alkaloids and other natural products.</data>
      <data key="v_atc_1">Vindesine is anatomically related to antineoplastic and immunomodulating agents.</data>
      <data key="v_molecular_weight">The molecular weight is 753.94.</data>
      <data key="v_atc_2">Vindesine is in the therapeutic group of antineoplastic agents.</data>
      <data key="v_tpsa">Vindesine has a topological polar surface area of 164.82.</data>
      <data key="v_atc_4">The chemical and functional group of  is vinca alkaloids and analogues.</data>
      <data key="v_clogp">The log p value of  is 3.42.</data>
      <data key="v_pathway">Vindesine uses Vindesine Action Pathway.</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n37">
      <data key="v_name">15970</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB12323</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Radotinib</data>
      <data key="v_indication">Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">Philadelphia chromosome positive (Ph+) leukemia is driven by the constitutive enzymatic activity of the BCR-ABL1 fusion kinase. Tyrosine kinase inhibitors (TKIs) that block the activity of BCR-ABL1 are successfully used clinically to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). </data>
      <data key="v_group">Radotinib is investigational.</data>
      <data key="v_category">Radotinib is part of Acids, Carbocyclic ; Amides ; Benzene Derivatives ; Benzoates ; Tyrosine Kinase Inhibitors.</data>
      <data key="v_description">Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">The molecular weight is 530.52.</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">Radotinib has a topological polar surface area of 110.51.</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">The log p value of  is 4.94.</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n38">
      <data key="v_name">19886</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB04865</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Omacetaxine mepesuccinate</data>
      <data key="v_indication">Used in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. </data>
      <data key="v_pharmacodynamics">The pharmacodynamics of homoharringtonine is not fully understood. It is known that homoharringtonine is involved</data>
      <data key="v_mechanism_of_action">Homoharringtonine inhibits protein synthesis by not directly binding to Bcr-Abl. It binds to the A-site cleft in the large ribosomal subunit, which affects chain elongation and prevents protein synthesis.</data>
      <data key="v_group">Omacetaxine mepesuccinate is approved and investigational.</data>
      <data key="v_category">Omacetaxine mepesuccinate is part of Alkaloids ; Antineoplastic Agents ; Antineoplastic Agents, Phytogenic ; Antineoplastic and Immunomodulating Agents ; Benzazepines ; Enzyme Inhibitors ; Harringtonines ; Heterocyclic Compounds, Fused-Ring ; Narrow Therapeutic Index Drugs ; Protein Synthesis Inhibitors.</data>
      <data key="v_description">Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.</data>
      <data key="v_state">Omacetaxine mepesuccinate is a solid.</data>
      <data key="v_protein_binding">Plasma protein binding is equal or less than 50%.</data>
      <data key="v_half_life">Homoharringtonine has a half life of about 6 hours after subcutaneous administration.</data>
      <data key="v_atc_3">Omacetaxine mepesuccinate is pharmacologically related to other antineoplastic agents.</data>
      <data key="v_atc_1">Omacetaxine mepesuccinate is anatomically related to antineoplastic and immunomodulating agents.</data>
      <data key="v_molecular_weight">The molecular weight is 545.63.</data>
      <data key="v_atc_2">Omacetaxine mepesuccinate is in the therapeutic group of antineoplastic agents.</data>
      <data key="v_tpsa">Omacetaxine mepesuccinate has a topological polar surface area of 123.99.</data>
      <data key="v_atc_4">The chemical and functional group of  is other antineoplastic agents.</data>
      <data key="v_clogp">The log p value of  is 2.33.</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n39">
      <data key="v_name">20473</data>
      <data key="v_type">drug</data>
      <data key="v_identifier">DB00791</data>
      <data key="v_source">DrugBank</data>
      <data key="v_label">Uracil mustard</data>
      <data key="v_indication">Used for its antineoplastic properties.</data>
      <data key="v_pharmacodynamics">Uracil Mustard selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Uracil Mustard-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.</data>
      <data key="v_mechanism_of_action">After activation, it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.</data>
      <data key="v_group">Uracil mustard is approved.</data>
      <data key="v_category">Uracil mustard is part of Alkylating Drugs ; Antineoplastic Agents ; Antineoplastic Agents, Alkylating ; Antineoplastic and Immunomodulating Agents ; Hydrocarbons, Halogenated ; Mustard Compounds ; Narrow Therapeutic Index Drugs ; Nitrogen Mustard Compounds ; Nitrosoureas ; Noxae ; Pyrimidines ; Pyrimidinones ; Toxic Actions.</data>
      <data key="v_description">Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.</data>
      <data key="v_state">Uracil mustard is a solid.</data>
      <data key="v_protein_binding">5%</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">Uracil mustard is pharmacologically related to alkylating agents.</data>
      <data key="v_atc_1">Uracil mustard is anatomically related to antineoplastic and immunomodulating agents.</data>
      <data key="v_molecular_weight">The molecular weight is 252.1.</data>
      <data key="v_atc_2">Uracil mustard is in the therapeutic group of antineoplastic agents.</data>
      <data key="v_tpsa">Uracil mustard has a topological polar surface area of 61.44.</data>
      <data key="v_atc_4">The chemical and functional group of  is nitrosoureas.</data>
      <data key="v_clogp">The log p value of  is 0.6.</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n40">
      <data key="v_name">22757</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">1428</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Somatic mutation</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n41">
      <data key="v_name">22916</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">1871</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Abnormality of blood and blood-forming tissues</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n42">
      <data key="v_name">22918</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">1911</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Abnormal granulocyte morphology</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n43">
      <data key="v_name">22923</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">1974</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Leukocytosis</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n44">
      <data key="v_name">22934</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">1873</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Thrombocytopenia</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n45">
      <data key="v_name">22952</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">1945</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Fever</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n46">
      <data key="v_name">24143</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">1744</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Splenomegaly</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n47">
      <data key="v_name">24478</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">4852</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Reduced leukocyte alkaline phosphatase</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n48">
      <data key="v_name">25620</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">12378</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Fatigue</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n49">
      <data key="v_name">26281</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">1912</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Abnormal basophil morphology</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n50">
      <data key="v_name">28520</data>
      <data key="v_type">disease</data>
      <data key="v_identifier">18874_4643</data>
      <data key="v_source">MONDO_grouped</data>
      <data key="v_label">myeloid leukemia</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">myeloid leukemia</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">myeloid leukemia</data>
      <data key="v_mondo_definition">A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">18874_4643</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_mondo_id">4643</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">Factors that may increase your risk of developing some types of leukemia include: Previous cancer treatment. People who&apos;ve had certain types of chemotherapy and radiation therapy for other cancers have an increased risk of developing certain types of leukemia. Genetic disorders. Genetic abnormalities seem to play a role in the development of leukemia. Certain genetic disorders, such as Down syndrome, are associated with an increased risk of leukemia. Exposure to certain chemicals. Exposure to certain chemicals, such as benzene  which is found in gasoline and is used by the chemical industry  is linked to an increased risk of some kinds of leukemia. Smoking. Smoking cigarettes increases the risk of acute myelogenous leukemia. Family history of leukemia. If members of your family have been diagnosed with leukemia, your risk of the disease may be increased. However, most people with known risk factors don&apos;t get leukemia. And many people with leukemia have none of these risk factors.</data>
      <data key="v_mayo_causes">Scientists don&apos;t understand the exact causes of leukemia. It seems to develop from a combination of genetic and environmental factors. How leukemia forms, In general, leukemia is thought to occur when some blood cells acquire changes in their genetic material or DNA. A cell&apos;s DNA contains the instructions that tell a cell what to do. Normally, the DNA tells the cell to grow at a set rate and to die at a set time. In leukemia, the mutations tell the blood cells to continue growing and dividing. When this happens, blood cell production becomes out of control. Over time, these abnormal cells can crowd out healthy blood cells in the bone marrow, leading to fewer healthy white blood cells, red blood cells and platelets, causing the signs and symptoms of leukemia. How leukemia is classified, Doctors classify leukemia based on its speed of progression and the type of cells involved. The first type of classification is by how fast the leukemia progresses: Acute leukemia. In acute leukemia, the abnormal blood cells are immature blood cells . They can&apos;t carry out their normal functions, and they multiply rapidly, so the disease worsens quickly. Acute leukemia requires aggressive, timely treatment. Chronic leukemia. There are many types of chronic leukemias. Some produce too many cells and some cause too few cells to be produced. Chronic leukemia involves more-mature blood cells. These blood cells replicate or accumulate more slowly and can function normally for a period of time. Some forms of chronic leukemia initially produce no early symptoms and can go unnoticed or undiagnosed for years. The second type of classification is by type of white blood cell affected: Lymphocytic leukemia. This type of leukemia affects the lymphoid cells, which form lymphoid or lymphatic tissue. Lymphatic tissue makes up your immune system. Myelogenous leukemia. This type of leukemia affects the myeloid cells. Myeloid cells give rise to red blood cells, white blood cells and platelet-producing cells. Types of leukemia, The major types of leukemia are: Acute lymphocytic leukemia . This is the most common type of leukemia in young children. ALL can also occur in adults. Acute myelogenous leukemia . AML is a common type of leukemia. It occurs in children and adults. AML is the most common type of acute leukemia in adults. Chronic lymphocytic leukemia . With CLL, the most common chronic adult leukemia, you may feel well for years without needing treatment. Chronic myelogenous leukemia . This type of leukemia mainly affects adults. A person with CML may have few or no symptoms for months or years before entering a phase in which the leukemia cells grow more quickly. Other types. Other, rarer types of leukemia exist, including hairy cell leukemia, myelodysplastic syndromes and myeloproliferative disorders.</data>
      <data key="v_mayo_symptoms">Leukemia symptoms vary, depending on the type of leukemia. Common leukemia signs and symptoms include: Fever or chills, Persistent fatigue, weakness, Frequent or severe infections, Losing weight without trying, Swollen lymph nodes, enlarged liver or spleen, Easy bleeding or bruising, Recurrent nosebleeds, Tiny red spots in your skin, Excessive sweating, especially at night, Bone pain or tenderness</data>
      <data key="v_mayo_see_doc">When to see a doctor, Make an appointment with your doctor if you have any persistent signs or symptoms that worry you. Leukemia symptoms are often vague and not specific. You may overlook early leukemia symptoms because they may resemble symptoms of the flu and other common illnesses. Sometimes leukemia is discovered during blood tests for some other condition.</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n51">
      <data key="v_name">29138</data>
      <data key="v_type">disease</data>
      <data key="v_identifier">10809</data>
      <data key="v_source">MONDO</data>
      <data key="v_label">familial chronic myelocytic leukemia-like syndrome</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">familial chronic myelocytic leukemia-like syndrome</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">A chronic myeloid leukemia characterized by chronic myelocytic leukemia in early infancy and absence of the BCR/ABL fusion gene (Philadelphia chromosome).</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_mondo_id">10809</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">Factors that may increase your risk of developing some types of leukemia include: Previous cancer treatment. People who&apos;ve had certain types of chemotherapy and radiation therapy for other cancers have an increased risk of developing certain types of leukemia. Genetic disorders. Genetic abnormalities seem to play a role in the development of leukemia. Certain genetic disorders, such as Down syndrome, are associated with an increased risk of leukemia. Exposure to certain chemicals. Exposure to certain chemicals, such as benzene  which is found in gasoline and is used by the chemical industry  is linked to an increased risk of some kinds of leukemia. Smoking. Smoking cigarettes increases the risk of acute myelogenous leukemia. Family history of leukemia. If members of your family have been diagnosed with leukemia, your risk of the disease may be increased. However, most people with known risk factors don&apos;t get leukemia. And many people with leukemia have none of these risk factors.</data>
      <data key="v_mayo_causes">Scientists don&apos;t understand the exact causes of leukemia. It seems to develop from a combination of genetic and environmental factors. How leukemia forms, In general, leukemia is thought to occur when some blood cells acquire changes in their genetic material or DNA. A cell&apos;s DNA contains the instructions that tell a cell what to do. Normally, the DNA tells the cell to grow at a set rate and to die at a set time. In leukemia, the mutations tell the blood cells to continue growing and dividing. When this happens, blood cell production becomes out of control. Over time, these abnormal cells can crowd out healthy blood cells in the bone marrow, leading to fewer healthy white blood cells, red blood cells and platelets, causing the signs and symptoms of leukemia. How leukemia is classified, Doctors classify leukemia based on its speed of progression and the type of cells involved. The first type of classification is by how fast the leukemia progresses: Acute leukemia. In acute leukemia, the abnormal blood cells are immature blood cells . They can&apos;t carry out their normal functions, and they multiply rapidly, so the disease worsens quickly. Acute leukemia requires aggressive, timely treatment. Chronic leukemia. There are many types of chronic leukemias. Some produce too many cells and some cause too few cells to be produced. Chronic leukemia involves more-mature blood cells. These blood cells replicate or accumulate more slowly and can function normally for a period of time. Some forms of chronic leukemia initially produce no early symptoms and can go unnoticed or undiagnosed for years. The second type of classification is by type of white blood cell affected: Lymphocytic leukemia. This type of leukemia affects the lymphoid cells, which form lymphoid or lymphatic tissue. Lymphatic tissue makes up your immune system. Myelogenous leukemia. This type of leukemia affects the myeloid cells. Myeloid cells give rise to red blood cells, white blood cells and platelet-producing cells. Types of leukemia, The major types of leukemia are: Acute lymphocytic leukemia . This is the most common type of leukemia in young children. ALL can also occur in adults. Acute myelogenous leukemia . AML is a common type of leukemia. It occurs in children and adults. AML is the most common type of acute leukemia in adults. Chronic lymphocytic leukemia . With CLL, the most common chronic adult leukemia, you may feel well for years without needing treatment. Chronic myelogenous leukemia . This type of leukemia mainly affects adults. A person with CML may have few or no symptoms for months or years before entering a phase in which the leukemia cells grow more quickly. Other types. Other, rarer types of leukemia exist, including hairy cell leukemia, myelodysplastic syndromes and myeloproliferative disorders.</data>
      <data key="v_mayo_symptoms">Leukemia symptoms vary, depending on the type of leukemia. Common leukemia signs and symptoms include: Fever or chills, Persistent fatigue, weakness, Frequent or severe infections, Losing weight without trying, Swollen lymph nodes, enlarged liver or spleen, Easy bleeding or bruising, Recurrent nosebleeds, Tiny red spots in your skin, Excessive sweating, especially at night, Bone pain or tenderness</data>
      <data key="v_mayo_see_doc">When to see a doctor, Make an appointment with your doctor if you have any persistent signs or symptoms that worry you. Leukemia symptoms are often vague and not specific. You may overlook early leukemia symptoms because they may resemble symptoms of the flu and other common illnesses. Sometimes leukemia is discovered during blood tests for some other condition.</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n52">
      <data key="v_name">30039</data>
      <data key="v_type">disease</data>
      <data key="v_identifier">11996</data>
      <data key="v_source">MONDO</data>
      <data key="v_label">chronic myelogenous leukemia, BCR-ABL1 positive</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">chronic myelogenous leukemia, BCR-ABL1 positive</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.</data>
      <data key="v_orphanet_epidemiology">Its annual incidence has been estimated at between 1 and 1.5 cases per 100000 and its prevalence at around 1 in 17000.</data>
      <data key="v_orphanet_definition">Chronic myeloid leukaemia (CML) is the most common myeloproliferative disorder accounting for 15-20% of all leukaemia cases.</data>
      <data key="v_orphanet_prevalence">1-9/100000</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">Although an allogeneic bone marrow transplant is viewed as the only curative treatment option, the prognosis for patients improved dramatically with the targeted development of imatinib mesylate. Imatinib mesylate is a competitive inhibitor of BCR/ABL tyrosine kinase activity and has held EU marketing authorisation as an Orphan drug for the treatment of CML since 2001.</data>
      <data key="v_mondo_id">11996</data>
      <data key="v_orphanet_clinical_description">The disease is typically triphasic with a chronic phase (CML-CP), accelerated phase (CML-AP) and blast phase (CML-BP). The majority of patients are diagnosed in the chronic phase and may be either asymptomatic (diagnosed through a routine white blood cell count) or present with fatigue, anaemia, weight loss, night sweats or splenomegaly.</data>
      <data key="v_mayo_risk_factors">Factors that increase the risk of chronic myelogenous leukemia: Older age, Being male, Radiation exposure, such as radiation therapy for certain types of cancer, Family history is not a risk factor, The mutation that leads to chronic myelogenous leukemia isn&apos;t passed from parents to children. This mutation is believed to be acquired, meaning it develops after birth.</data>
      <data key="v_mayo_causes">Chronic myelogenous leukemia occurs when something goes awry in the genes of your bone marrow cells. It&apos;s not clear what initially sets off this process, but doctors have discovered how it progresses into chronic myelogenous leukemia. An abnormal chromosome develops, Human cells normally contain 23 pairs of chromosomes. These chromosomes hold the DNA that contains the instructions that control the cells in your body. In people with chronic myelogenous leukemia, the chromosomes in the blood cells swap sections with each other. A section of chromosome 9 switches places with a section of chromosome 22, creating an extra-short chromosome 22 and an extra-long chromosome 9. The extra-short chromosome 22 is called the Philadelphia chromosome, named for the city where it was discovered. The Philadelphia chromosome is present in the blood cells of 90 percent of people with chronic myelogenous leukemia. The abnormal chromosome creates a new gene, The Philadelphia chromosome creates a new gene. Genes from chromosome 9 combine with genes from chromosome 22 to create a new gene called BCR-ABL. The BCR-ABL gene contains instructions that tell the abnormal blood cell to produce too much of a protein called tyrosine kinase. Tyrosine kinase promotes cancer by allowing certain blood cells to grow out of control. The new gene allows too many diseased blood cells, Your blood cells originate in the bone marrow, a spongy material inside your bones. When your bone marrow functions normally, it produces immature cells in a controlled way. These cells then mature and specialize into the various types of blood cells that circulate in your body  red cells, white cells and platelets. In chronic myelogenous leukemia, this process doesn&apos;t work properly. The tyrosine kinase caused by the BCR-ABL gene allows too many white blood cells to grow. Most or all of these cells contain the abnormal Philadelphia chromosome. The diseased white blood cells don&apos;t grow and die like normal cells. The diseased white blood cells build up in huge numbers, crowding out healthy blood cells and damaging the bone marrow.</data>
      <data key="v_mayo_symptoms">Chronic myelogenous leukemia often doesn&apos;t cause signs and symptoms. It might be detected during a blood test. When they occur, signs and symptoms may include: Bone pain, Easy bleeding, Feeling full after eating a small amount of food, Feeling run-down or tired, Fever, Weight loss without trying, Loss of appetite, Pain or fullness below the ribs on the left side, Excessive sweating during sleep </data>
      <data key="v_mayo_see_doc">When to see a doctor, Make an appointment with your doctor if you have any persistent signs or symptoms that worry you.</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n53">
      <data key="v_name">33749</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">5547</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Myeloproliferative disorder</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n54">
      <data key="v_name">84261</data>
      <data key="v_type">disease</data>
      <data key="v_identifier">6115</data>
      <data key="v_source">MONDO</data>
      <data key="v_label">blast phase chronic myelogenous leukemia, BCR-ABL1 positive</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">blast phase chronic myelogenous leukemia, BCR-ABL1 positive</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">An advanced phase of chronic myelogenous leukemia. It is characterized by: 1. the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_mondo_id">6115</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">Factors that increase the risk of chronic myelogenous leukemia: Older age, Being male, Radiation exposure, such as radiation therapy for certain types of cancer, Family history is not a risk factor, The mutation that leads to chronic myelogenous leukemia isn&apos;t passed from parents to children. This mutation is believed to be acquired, meaning it develops after birth.</data>
      <data key="v_mayo_causes">Chronic myelogenous leukemia occurs when something goes awry in the genes of your bone marrow cells. It&apos;s not clear what initially sets off this process, but doctors have discovered how it progresses into chronic myelogenous leukemia. An abnormal chromosome develops, Human cells normally contain 23 pairs of chromosomes. These chromosomes hold the DNA that contains the instructions that control the cells in your body. In people with chronic myelogenous leukemia, the chromosomes in the blood cells swap sections with each other. A section of chromosome 9 switches places with a section of chromosome 22, creating an extra-short chromosome 22 and an extra-long chromosome 9. The extra-short chromosome 22 is called the Philadelphia chromosome, named for the city where it was discovered. The Philadelphia chromosome is present in the blood cells of 90 percent of people with chronic myelogenous leukemia. The abnormal chromosome creates a new gene, The Philadelphia chromosome creates a new gene. Genes from chromosome 9 combine with genes from chromosome 22 to create a new gene called BCR-ABL. The BCR-ABL gene contains instructions that tell the abnormal blood cell to produce too much of a protein called tyrosine kinase. Tyrosine kinase promotes cancer by allowing certain blood cells to grow out of control. The new gene allows too many diseased blood cells, Your blood cells originate in the bone marrow, a spongy material inside your bones. When your bone marrow functions normally, it produces immature cells in a controlled way. These cells then mature and specialize into the various types of blood cells that circulate in your body  red cells, white cells and platelets. In chronic myelogenous leukemia, this process doesn&apos;t work properly. The tyrosine kinase caused by the BCR-ABL gene allows too many white blood cells to grow. Most or all of these cells contain the abnormal Philadelphia chromosome. The diseased white blood cells don&apos;t grow and die like normal cells. The diseased white blood cells build up in huge numbers, crowding out healthy blood cells and damaging the bone marrow.</data>
      <data key="v_mayo_symptoms">Chronic myelogenous leukemia often doesn&apos;t cause signs and symptoms. It might be detected during a blood test. When they occur, signs and symptoms may include: Bone pain, Easy bleeding, Feeling full after eating a small amount of food, Feeling run-down or tired, Fever, Weight loss without trying, Loss of appetite, Pain or fullness below the ribs on the left side, Excessive sweating during sleep </data>
      <data key="v_mayo_see_doc">When to see a doctor, Make an appointment with your doctor if you have any persistent signs or symptoms that worry you.</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n55">
      <data key="v_name">84993</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">1894</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Thrombocytosis</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n56">
      <data key="v_name">85849</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">4396</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Poor appetite</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n57">
      <data key="v_name">86289</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">5506</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Chronic myelogenous leukemia</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n58">
      <data key="v_name">94316</data>
      <data key="v_type">effect/phenotype</data>
      <data key="v_identifier">4848</data>
      <data key="v_source">HPO</data>
      <data key="v_label">Ph-positive acute lymphoblastic leukemia</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">None</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">None</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">None</data>
      <data key="v_mayo_causes">None</data>
      <data key="v_mayo_symptoms">None</data>
      <data key="v_mayo_see_doc">None</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <node id="n59">
      <data key="v_name">94757</data>
      <data key="v_type">disease</data>
      <data key="v_identifier">21367</data>
      <data key="v_source">MONDO</data>
      <data key="v_label">leukemia, myeloid, accelerated-phase</data>
      <data key="v_indication">None</data>
      <data key="v_pharmacodynamics">None</data>
      <data key="v_mechanism_of_action">None</data>
      <data key="v_group">None</data>
      <data key="v_category">None</data>
      <data key="v_description">None</data>
      <data key="v_state">None</data>
      <data key="v_protein_binding">None</data>
      <data key="v_half_life">None</data>
      <data key="v_atc_3">None</data>
      <data key="v_atc_1">None</data>
      <data key="v_molecular_weight">None</data>
      <data key="v_atc_2">None</data>
      <data key="v_tpsa">None</data>
      <data key="v_atc_4">None</data>
      <data key="v_clogp">None</data>
      <data key="v_pathway">None</data>
      <data key="v_mondo_name">leukemia, myeloid, accelerated-phase</data>
      <data key="v_umls_description">false</data>
      <data key="v_group_name_bert">None</data>
      <data key="v_mondo_definition">The phase of chronic myeloid leukemia following the chronic phase (leukemia, myeloid, chronic-phase), where there are increased systemic symptoms, worsening cytopenias, and refractory leukocytosis.</data>
      <data key="v_orphanet_epidemiology">None</data>
      <data key="v_orphanet_definition">None</data>
      <data key="v_orphanet_prevalence">None</data>
      <data key="v_group_id_bert">None</data>
      <data key="v_orphanet_management_and_treatment">None</data>
      <data key="v_mondo_id">21367</data>
      <data key="v_orphanet_clinical_description">None</data>
      <data key="v_mayo_risk_factors">Factors that may increase your risk of developing some types of leukemia include: Previous cancer treatment. People who&apos;ve had certain types of chemotherapy and radiation therapy for other cancers have an increased risk of developing certain types of leukemia. Genetic disorders. Genetic abnormalities seem to play a role in the development of leukemia. Certain genetic disorders, such as Down syndrome, are associated with an increased risk of leukemia. Exposure to certain chemicals. Exposure to certain chemicals, such as benzene  which is found in gasoline and is used by the chemical industry  is linked to an increased risk of some kinds of leukemia. Smoking. Smoking cigarettes increases the risk of acute myelogenous leukemia. Family history of leukemia. If members of your family have been diagnosed with leukemia, your risk of the disease may be increased. However, most people with known risk factors don&apos;t get leukemia. And many people with leukemia have none of these risk factors.</data>
      <data key="v_mayo_causes">Scientists don&apos;t understand the exact causes of leukemia. It seems to develop from a combination of genetic and environmental factors. How leukemia forms, In general, leukemia is thought to occur when some blood cells acquire changes in their genetic material or DNA. A cell&apos;s DNA contains the instructions that tell a cell what to do. Normally, the DNA tells the cell to grow at a set rate and to die at a set time. In leukemia, the mutations tell the blood cells to continue growing and dividing. When this happens, blood cell production becomes out of control. Over time, these abnormal cells can crowd out healthy blood cells in the bone marrow, leading to fewer healthy white blood cells, red blood cells and platelets, causing the signs and symptoms of leukemia. How leukemia is classified, Doctors classify leukemia based on its speed of progression and the type of cells involved. The first type of classification is by how fast the leukemia progresses: Acute leukemia. In acute leukemia, the abnormal blood cells are immature blood cells . They can&apos;t carry out their normal functions, and they multiply rapidly, so the disease worsens quickly. Acute leukemia requires aggressive, timely treatment. Chronic leukemia. There are many types of chronic leukemias. Some produce too many cells and some cause too few cells to be produced. Chronic leukemia involves more-mature blood cells. These blood cells replicate or accumulate more slowly and can function normally for a period of time. Some forms of chronic leukemia initially produce no early symptoms and can go unnoticed or undiagnosed for years. The second type of classification is by type of white blood cell affected: Lymphocytic leukemia. This type of leukemia affects the lymphoid cells, which form lymphoid or lymphatic tissue. Lymphatic tissue makes up your immune system. Myelogenous leukemia. This type of leukemia affects the myeloid cells. Myeloid cells give rise to red blood cells, white blood cells and platelet-producing cells. Types of leukemia, The major types of leukemia are: Acute lymphocytic leukemia . This is the most common type of leukemia in young children. ALL can also occur in adults. Acute myelogenous leukemia . AML is a common type of leukemia. It occurs in children and adults. AML is the most common type of acute leukemia in adults. Chronic lymphocytic leukemia . With CLL, the most common chronic adult leukemia, you may feel well for years without needing treatment. Chronic myelogenous leukemia . This type of leukemia mainly affects adults. A person with CML may have few or no symptoms for months or years before entering a phase in which the leukemia cells grow more quickly. Other types. Other, rarer types of leukemia exist, including hairy cell leukemia, myelodysplastic syndromes and myeloproliferative disorders.</data>
      <data key="v_mayo_symptoms">Leukemia symptoms vary, depending on the type of leukemia. Common leukemia signs and symptoms include: Fever or chills, Persistent fatigue, weakness, Frequent or severe infections, Losing weight without trying, Swollen lymph nodes, enlarged liver or spleen, Easy bleeding or bruising, Recurrent nosebleeds, Tiny red spots in your skin, Excessive sweating, especially at night, Bone pain or tenderness</data>
      <data key="v_mayo_see_doc">When to see a doctor, Make an appointment with your doctor if you have any persistent signs or symptoms that worry you. Leukemia symptoms are often vague and not specific. You may overlook early leukemia symptoms because they may resemble symptoms of the flu and other common illnesses. Sometimes leukemia is discovered during blood tests for some other condition.</data>
      <data key="v_mayo_prevention">false</data>
      <data key="v_mayo_complications">false</data>
    </node>
    <edge source="n0" target="n3">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n0" target="n31">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n0" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n1" target="n4">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n1" target="n5">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n1" target="n9">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n1" target="n14">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n1" target="n20">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n1" target="n29">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n1" target="n31">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n1" target="n33">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n1" target="n35">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n1" target="n37">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n1" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n2" target="n6">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n2" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n3" target="n0">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n3" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n4" target="n1">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n4" target="n5">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n4" target="n29">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n4" target="n31">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n4" target="n33">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n4" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n4" target="n54">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n5" target="n1">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n5" target="n4">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n5" target="n50">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n5" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n6" target="n2">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n6" target="n20">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n6" target="n22">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n6" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n7" target="n8">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n7" target="n11">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n7" target="n17">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n7" target="n19">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n7" target="n23">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n7" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n8" target="n7">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n8" target="n11">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n8" target="n17">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n8" target="n19">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n8" target="n23">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n8" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n9" target="n1">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n9" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n10" target="n44">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n10" target="n50">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n10" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n11" target="n7">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n11" target="n8">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n11" target="n19">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n11" target="n23">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n11" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n12" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n13" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n14" target="n1">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n14" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n15" target="n50">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n15" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n16" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n17" target="n7">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n17" target="n8">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n17" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n18" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n19" target="n7">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n19" target="n8">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n19" target="n11">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n19" target="n23">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n19" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n20" target="n1">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n20" target="n6">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n20" target="n50">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n20" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n21" target="n50">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n21" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n22" target="n6">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n22" target="n43">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n22" target="n46">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n22" target="n50">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n22" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n23" target="n7">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n23" target="n8">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n23" target="n11">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n23" target="n19">
      <data key="e_type">protein_protein</data>
      <data key="e_display_relation">ppi</data>
    </edge>
    <edge source="n23" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n24" target="n43">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n24" target="n50">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n24" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n25" target="n44">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n25" target="n45">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n25" target="n48">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n25" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n26" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n27" target="n50">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n27" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n28" target="n52">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n29" target="n1">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n29" target="n4">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n29" target="n30">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n29" target="n31">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n29" target="n32">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n29" target="n33">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n29" target="n34">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n29" target="n35">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n29" target="n36">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n29" target="n44">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n29" target="n45">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n29" target="n48">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n29" target="n52">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n29" target="n54">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n29" target="n55">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n29" target="n56">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n29" target="n57">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n30" target="n29">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n30" target="n31">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n30" target="n32">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n30" target="n33">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n30" target="n34">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n30" target="n35">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n30" target="n36">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n30" target="n41">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n30" target="n44">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n30" target="n45">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n30" target="n48">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n30" target="n50">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n30" target="n52">
      <data key="e_type">off-label use</data>
      <data key="e_display_relation">off-label use</data>
    </edge>
    <edge source="n30" target="n56">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n31" target="n0">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n31" target="n1">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n31" target="n4">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n31" target="n29">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n31" target="n30">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n31" target="n32">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n31" target="n33">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n31" target="n34">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n31" target="n35">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n31" target="n36">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n31" target="n44">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n31" target="n45">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n31" target="n48">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n31" target="n52">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n31" target="n54">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n31" target="n56">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n31" target="n57">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n32" target="n29">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n32" target="n30">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n32" target="n31">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n32" target="n33">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n32" target="n34">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n32" target="n35">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n32" target="n36">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n32" target="n44">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n32" target="n52">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n32" target="n56">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n33" target="n1">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n33" target="n4">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n33" target="n29">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n33" target="n30">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n33" target="n31">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n33" target="n32">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n33" target="n34">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n33" target="n35">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n33" target="n36">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n33" target="n52">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n34" target="n29">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n34" target="n30">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n34" target="n31">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n34" target="n32">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n34" target="n33">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n34" target="n35">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n34" target="n36">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n34" target="n44">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n34" target="n45">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n34" target="n48">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n34" target="n52">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n34" target="n56">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n34" target="n57">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n35" target="n1">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n35" target="n29">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n35" target="n30">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n35" target="n31">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n35" target="n32">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n35" target="n33">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n35" target="n34">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n35" target="n36">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n35" target="n43">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n35" target="n44">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n35" target="n45">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n35" target="n48">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n35" target="n52">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n35" target="n55">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n35" target="n56">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n36" target="n29">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n36" target="n30">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n36" target="n31">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n36" target="n32">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n36" target="n33">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n36" target="n34">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n36" target="n35">
      <data key="e_type">drug_drug</data>
      <data key="e_display_relation">synergistic interaction</data>
    </edge>
    <edge source="n36" target="n52">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n37" target="n1">
      <data key="e_type">drug_protein</data>
      <data key="e_display_relation">target</data>
    </edge>
    <edge source="n37" target="n52">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n38" target="n52">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n39" target="n52">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n40" target="n50">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n40" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n41" target="n30">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n41" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n42" target="n49">
      <data key="e_type">phenotype_phenotype</data>
      <data key="e_display_relation">parent-child</data>
    </edge>
    <edge source="n42" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n43" target="n22">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n43" target="n24">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n43" target="n35">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n43" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n44" target="n10">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n44" target="n25">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n44" target="n29">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n44" target="n30">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n44" target="n31">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n44" target="n32">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n44" target="n34">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n44" target="n35">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n44" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n45" target="n25">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n45" target="n29">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n45" target="n30">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n45" target="n31">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n45" target="n34">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n45" target="n35">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n45" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n46" target="n22">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n46" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n47" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n48" target="n25">
      <data key="e_type">phenotype_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n48" target="n29">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n48" target="n30">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n48" target="n31">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n48" target="n34">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n48" target="n35">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n48" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n49" target="n42">
      <data key="e_type">phenotype_phenotype</data>
      <data key="e_display_relation">parent-child</data>
    </edge>
    <edge source="n49" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n50" target="n5">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n50" target="n10">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n50" target="n15">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n50" target="n20">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n50" target="n21">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n50" target="n22">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n50" target="n24">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n50" target="n27">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n50" target="n30">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n50" target="n40">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n50" target="n52">
      <data key="e_type">disease_disease</data>
      <data key="e_display_relation">parent-child</data>
    </edge>
    <edge source="n51" target="n52">
      <data key="e_type">disease_disease</data>
      <data key="e_display_relation">parent-child</data>
    </edge>
    <edge source="n51" target="n57">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n0">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n1">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n2">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n3">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n4">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n5">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n6">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n7">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n8">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n9">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n10">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n11">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n12">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n13">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n14">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n15">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n16">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n17">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n18">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n19">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n20">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n21">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n22">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n23">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n24">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n25">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n26">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n27">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n28">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n52" target="n29">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n52" target="n30">
      <data key="e_type">off-label use</data>
      <data key="e_display_relation">off-label use</data>
    </edge>
    <edge source="n52" target="n31">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n52" target="n32">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n52" target="n33">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n52" target="n34">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n52" target="n35">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n52" target="n36">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n52" target="n37">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n52" target="n38">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n52" target="n39">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n52" target="n40">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n41">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n42">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n43">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n44">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n45">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n46">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n47">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n48">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n49">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n50">
      <data key="e_type">disease_disease</data>
      <data key="e_display_relation">parent-child</data>
    </edge>
    <edge source="n52" target="n51">
      <data key="e_type">disease_disease</data>
      <data key="e_display_relation">parent-child</data>
    </edge>
    <edge source="n52" target="n53">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n54">
      <data key="e_type">disease_disease</data>
      <data key="e_display_relation">parent-child</data>
    </edge>
    <edge source="n52" target="n55">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n56">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n57">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n58">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n52" target="n59">
      <data key="e_type">disease_disease</data>
      <data key="e_display_relation">parent-child</data>
    </edge>
    <edge source="n53" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n54" target="n4">
      <data key="e_type">disease_protein</data>
      <data key="e_display_relation">associated with</data>
    </edge>
    <edge source="n54" target="n29">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n54" target="n31">
      <data key="e_type">indication</data>
      <data key="e_display_relation">indication</data>
    </edge>
    <edge source="n54" target="n52">
      <data key="e_type">disease_disease</data>
      <data key="e_display_relation">parent-child</data>
    </edge>
    <edge source="n55" target="n29">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n55" target="n35">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n55" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n56" target="n29">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n56" target="n30">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n56" target="n31">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n56" target="n32">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n56" target="n34">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n56" target="n35">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n56" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n57" target="n29">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n57" target="n31">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n57" target="n34">
      <data key="e_type">drug_effect</data>
      <data key="e_display_relation">side effect</data>
    </edge>
    <edge source="n57" target="n51">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n57" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n58" target="n52">
      <data key="e_type">disease_phenotype_positive</data>
      <data key="e_display_relation">phenotype present</data>
    </edge>
    <edge source="n59" target="n52">
      <data key="e_type">disease_disease</data>
      <data key="e_display_relation">parent-child</data>
    </edge>
  </graph>
</graphml>
